1.Eccrine Angiomatous Hamartoma Treated by Intense Pulsed Light.
Tae Gwang KWON ; Hyun HWANGBO ; Young Seok LEE ; Sook Kyung LEE
Korean Journal of Dermatology 2014;52(2):136-137
No abstract available.
Hamartoma*
2.Mycobacterium abscessus Skin Infection Following the Embedding Therapy in a Oriental Clinic.
Hyun HWANGBO ; Seung Hyun MOON ; Se Won JUNG ; Sook Kyung LEE
Korean Journal of Dermatology 2016;54(2):155-156
No abstract available.
Mycobacterium*
;
Skin*
3.Complete Remission of Recalcitrant Plantar Wart Treated with Quadrivalent Human Papilloma Virus Vaccine.
Taek Geun LEE ; Hyun HWANGBO ; Se Won JUNG ; Sook Kyung LEE
Korean Journal of Dermatology 2014;52(6):442-443
No abstract available.
Humans
;
Papilloma*
;
Warts*
4.Pemphigus Vegetans on the Face.
Se Won JUNG ; Hyun HWANGBO ; Young Seok LEE ; Sook Kyung LEE
Korean Journal of Dermatology 2013;51(8):661-662
No abstract available.
Pemphigus
5.A Case of Papular Eruption Associated with Clonorchiasis.
Woo Seok JEONG ; Woo Jung JIN ; Seung Hyun MOON ; Hyun HWANGBO ; Sook Kyung LEE
Korean Journal of Dermatology 2018;56(7):457-458
No abstract available.
Clonorchiasis*
;
Clonorchis sinensis
6.A Case of Bilateral Renal Agenesis Diagnosed by Prenatal Ultrasonography.
Jung Eun MOK ; Chun HWANGBO ; Hye Sung WON ; Hye Kyung YOO ; Pyl Ryang LEE ; In Sik LEE ; Ahm KIM
Korean Journal of Obstetrics and Gynecology 1999;42(1):167-170
Fetal bilateral renal agenesis is a lethal congenital anomaly. An early and reliable prenatal diagnosis is extremely important as it may offer options for pregnancy termination as early as possible. The criteria for the ultrasonographic diagnosis of bilateral renal agenesis are severe oligohydramnios, nonvisualization of the bladder, and the empty renal fossae. However, severe oligohydramnios makes it difficult to diagnose the disease because of poor sonographic resolution. We present a case of fetal bilateral renal agenesis diagnosed by ultrasonography after amnioinfusion at 19 weeks gestation.
Diagnosis
;
Female
;
Oligohydramnios
;
Pregnancy
;
Prenatal Diagnosis
;
Ultrasonography
;
Ultrasonography, Prenatal*
;
Urinary Bladder
7.Hand-assisted Laparoscopic Donor Nephrectomy: A Comparison with Open Approach.
Kyung HWANGBO ; Joon Cheol KIM ; Tae Kon HWANG
Korean Journal of Urology 2002;43(6):449-453
PURPOSE: We report our initial experience with hand-assisted laparoscopic donor nephrectomy (HALDN) and compare it to our results with open donor nephrectomy (ODN). MATERIALS AND METHODS: Using the medical records of consecutive, renal, living donor-recipient pairs, 60 HALDN patients were compared with 19 ODN patients. In addition, the HALDN group was divided into two groups, initial HALDNs (n=20) and late HALDNs (n=40), for consideration of the surgeons' learning curve. RESULTS: Except 1 case of open conversion, 59 patients underwent HALDN successfully. Mean operation times were 202, 255, and 201 minutes for ODNs, initial HALDNs, and late HALDNs respectively. Mean warm ischemic time decreased from 4.5 minutes in the initial HALDNs to 3.1 minutes in the late HALDNs. Major intraoperative complications included 1 transfusion in the ODNs, 1 open conversion and 1 transfusion in the initial HALDNs, but none in the late HALDNs. Mean hospital stay decreased from 6.4 days in the ODNs to 4.6 and 3.8 days in the initial and late HALDNs, respectively. Mean analgesic use decreased from 403mg and 323mg in ODNs and initial HALDNs, respectively, to 219mg in late HALDNs. Serum creatinine levels of the recipients on post operation days 7 and 30 showed no differences among the three groups. CONCLUSIONS: All but one, HALDNs resulted in a safe donor operation with a kidney of excellent quality. The length of hospital stay and postoperative analgesic use were decreased. The cosmetic result was enhanced. Additionally, the number of living donors can be potentially increased.
Creatinine
;
Humans
;
Intraoperative Complications
;
Kidney
;
Laparoscopy
;
Learning Curve
;
Length of Stay
;
Living Donors
;
Medical Records
;
Nephrectomy*
;
Tissue Donors*
;
Warm Ischemia
8.Acute Hyperglycemia Associated with Anti-Cancer Medication.
Endocrinology and Metabolism 2017;32(1):23-29
Hyperglycemia during chemotherapy occurs in approximately 10% to 30% of patients. Glucocorticoids and L-asparaginase are well known to cause acute hyperglycemia during chemotherapy. Long-term hyperglycemia is also frequently observed, especially in patients with hematologic malignancies treated with L-asparaginase-based regimens and total body irradiation. Glucocorticoid-induced hyperglycemia often develops because of increased insulin resistance, diminished insulin secretion, and exaggerated hepatic glucose output. Screening strategies for this condition include random glucose testing, hemoglobin A1c testing, oral glucose loading, and fasting plasma glucose screens. The management of hyperglycemia starts with insulin or sulfonylurea, depending on the type, dose, and delivery of the glucocorticoid formulation. Mammalian target of rapamycin (mTOR) inhibitors are associated with a high incidence of hyperglycemia, ranging from 13% to 50%. Immunotherapy, such as anti-programmed death 1 (PD-1) antibody treatment, induces hyperglycemia with a prevalence of 0.1%. The proposed mechanism of immunotherapy-induced hyperglycemia is an autoimmune process (insulitis). Withdrawal of the PD-1 inhibitor is the primary treatment for severe hyperglycemia. The efficacy of glucocorticoid therapy is not fully established and the decision to resume PD-1 inhibitor therapy depends on the severity of the hyperglycemia. Diabetic patients should achieve optimized glycemic control before initiating treatment, and glucose levels should be monitored periodically in patients initiating mTOR inhibitor or PD-1 inhibitor therapy. With regard to hyperglycemia caused by anti-cancer therapy, frequent monitoring and proper management are important for promoting the efficacy of anti-cancer therapy and improving patients' quality of life.
Blood Glucose
;
Drug Therapy
;
Fasting
;
Glucocorticoids
;
Glucose
;
Hematologic Neoplasms
;
Humans
;
Hyperglycemia*
;
Immunotherapy
;
Incidence
;
Insulin
;
Insulin Resistance
;
Mass Screening
;
Prevalence
;
Quality of Life
;
Sirolimus
;
Whole-Body Irradiation
9.A Clinical Study using Quadrivalent Human Papilloma Virus (HPV) Vaccine for Treatment of Recalcitrant Wart.
Taek Geun LEE ; Hyun HWANGBO ; Sook Kyung LEE
Korean Journal of Dermatology 2016;54(8):614-621
BACKGROUND: Although several traditional treatments have been applied for recalcitrant viral warts, these treatments have rarely resulted in complete recovery. To treat the recalcitrant viral wart, alternative therapies are required. OBJECTIVE: This study aimed to evaluate the efficacy and safety of quadrivalent HPV vaccine for recalcitrant wart treatment. METHODS: From 2012 to 2014, 17 patients who provided informed consent were enrolled. All patients received 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months, respectively. During clinic visits, doctors checked the grade of improvement, patient satisfaction, and treatment side effects. After completion of the 3 doses, the patients were followed up for 5 months with outpatient visits and telephone inquiries. RESULTS: After the third dose, 58.8% of patients showed complete remission and 41.2% showed no response after 5 months. There were no statistically significant differences in sex, age, disease duration, number, anatomic site, and previous treatment between the complete remission group and the no-response group. An adverse effect (syncope) was observed in one patient. CONCLUSION: Compared with traditional aggressive therapies, quadrivalent HPV vaccine is a simple method and does not usually interfere with the patient's work or social life. Quadrivalent HPV vaccine is an effective and safe alternative treatment for recalcitrant warts.
Ambulatory Care
;
Clinical Study*
;
Complementary Therapies
;
Humans*
;
Informed Consent
;
Methods
;
Outpatients
;
Papillomaviridae*
;
Patient Satisfaction
;
Telephone
;
Warts*
10.The Diagnostic Distribution of Psychiatric Disorders among the Population Under 19 Years Old: Based on the National Insurance Data.
Ram HWANGBO ; Hyejung CHANG ; Minha HONG ; Seongwoo CHO ; Geon Ho BAHN
Journal of the Korean Academy of Child and Adolescent Psychiatry 2016;27(2):139-145
OBJECTIVES: As a preliminary study on the prevalence of mental disorders in Korean children and adolescents, we investigated the diagnosis distribution of mental disorders in people under 19 years of age using the health insurance data. METHODS: From the 2011 health insurance data of 1,375,842 people, the data of 286,465 people under 19 years old were extracted. Among them, we selected 10,778 with psychiatric diagnoses; male 6,453 (59.9%) and female 4,325 (40.1%). The frequency of psychiatric diagnoses in the males was 10,140 (62.7%) cases, which was significantly higher than that (6,031; 37.3%) in the females. We categorized the groups into 3 year intervals. RESULTS: In the males under 3 years old, F80 was the most prevalent diagnosis, followed by F98. F90 and F41 were the most prevalent in the 4-15 and above 16 years old groups, respectively. In the females, F98 was the most prevalent in the children up to 3 years old, while F80 was the second most prevalent. In the 4-6 years of age group, F98 was the most prevalent, followed by F93. F90 and F41 were predominant in the 7-12 and above 12 years old groups, respectively. CONCLUSION: In the analysis of the frequency of diagnosis of mental disorders in the population under 19 years old, there were significant differences in the distribution based on age and gender.
Adolescent
;
Child
;
Diagnosis
;
Female
;
Humans
;
Insurance*
;
Insurance, Health
;
Male
;
Mental Disorders
;
Prevalence